Azuria Water Solutions Announces the Acquisition of a portion of Miller Pipeline’s Municipal Services Division
06 nov. 2024 09h00 HE
|
Azuria Water Solutions
Azuria Water Solutions™ today announced the acquisition of a portion of Miller Pipeline LLC’s municipal services division operations.
Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024
11 oct. 2024 15h59 HE
|
Tevogen Bio Inc
Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024
Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID
11 oct. 2024 12h12 HE
|
Tevogen Bio Inc
Developing therapeutic products that not only treat cancer but also enable oncology patients to maintain uninterrupted therapy.Expanding its pipeline to include non-oncology products, an opportunistic...
Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress
26 sept. 2024 07h00 HE
|
Mural Oncology, Inc.
Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal...
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
12 juin 2024 16h01 HE
|
Barinthus Biotherapeutics
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
Azuria Announces Acquisition of Infrastructure Services Group LLC and Subsidiaries
11 juin 2024 10h36 HE
|
Azuria Water Solutions
Azuria Announces Acquisition of Infrastructure Services Group LLC and Subsidiaries
AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline and Announces New Development Program in Partnership with Boehringer Ingelheim
03 juin 2024 08h14 HE
|
AUROBAC THERAPEUTICS
AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June 3, 2024 AUROBAC THERAPEUTICS, a...
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
23 mai 2024 17h00 HE
|
Mural Oncology, Inc.
ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural’s late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3...
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
14 mai 2024 07h00 HE
|
Mural Oncology, Inc.
Mural Oncology reiterates cash runway projection into 4Q 2025, with sufficient capital to fund key clinical readouts.
Aegion Rebrands as Azuria Water Solutions, Signaling a New Era in Water Infrastructure Solutions
25 avr. 2024 13h58 HE
|
Azuria Water Solutions
Aegion Corporation today announced its official rebrand to Azuria Water Solutions, the leading provider of technology-enabled products and services.